Theratechnologies

Theratechnologies Inc. is a biopharmaceutical company dedicated to discovering therapeutic products for commercialization. The company's proprietary technology includes long-acting peptides, a peptide stabilization technology that increases the resistance of target proteins to enzymatic degradation. Its lead product, tesamorelin, completed Phase III clinical trials for the treatment of HIV-related lipodystrophy and is in Phase II clinical trials for the treatment of mild cognitive impairment and abdominal obesity associated with growth hormone deficiency. The company is also developing a preclinical-stage product for acute kidney injury.